Stock JNJ JOHNSON & JOHNSON
Add to a list
To use this feature you must be a member
Log inSign up

News Johnson & Johnson Börse Stuttgart

Equities

JNJ

US4781601046

Market Closed - Börse Stuttgart
Other stock markets
 13:15:20 2024-06-26 EDT 		After market 16:01:22
137.3 EUR -0.04% Intraday chart for Johnson & Johnson 137.4 +0.07%
06-24 US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit RE
06-24 J&J: 50M pupils helped through 'Sight for Kids' program CF

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program
AQ
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit
RE
J&J: 50M pupils helped through 'Sight for Kids' program
CF
Johnson & Johnson completes acquisition of Proteologix, Inc.
AQ
Sector Update: Health Care Stocks Edge Up in Afternoon Trading
MT
Johnson & Johnson: filing in Crohn's disease
CF
Johnson & Johnson: acquisition of Proteologix completed
CF
Johnson & Johnson Completes Acquisition of Proteologix
MT
Johnson & Johnson Completes Acquisition of Proteologix
MT
Johnson & Johnson Completes Acquisition of Proteologix
MT
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
BU
Health Authority Warns of Brain Risks From Pseudoephedrine Medications
AQ
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.
CI
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease
MT
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease
PR
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease
CI
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme
BU
J&J: launches open, secure digital ecosystem
CF
J&J: promising results in Crohn's disease
CF
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. JNJ Stock
  5. News Johnson & Johnson